Fragment condensation of a protected Pam3Cys lipopeptide with unprotected tumor-associated MUC1 glycopeptides opens the way to vaccine candidates such as A. These vaccines elicit selective immune responses in mice although they lack an immunodominant carrier protein. In principle, such vaccines are applicable to humans.
If you can't find a tool you're looking for, please click the link at the top of the page to "Go to old article view". Alternatively, view our Knowledge Base articles for additional help. Your feedback is important to us, so please let us know if you have comments or ideas for improvement.